The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Dallas P. Veitch; Michael W. Weiner; Melanie Miller; Paul S. Aisen; Miriam A. Ashford; Laurel A. Beckett; Robert C. Green; Danielle Harvey; Clifford R. Jack; William Jagust; Susan M. Landau; John C. Morris; Kwangsik T. Nho; Rachel Nosheny; Ozioma Okonkwo; Richard J. Perrin; Ronald C. Petersen; Monica Rivera Mindt; Andrew Saykin; Leslie M. Shaw; Arthur W. Toga; Duygu Tosun

doi:10.1002/alz.13449

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Dallas P. Veitch, Michael W. Weiner, Melanie Miller, Paul S. Aisen, Miriam A. Ashford, Laurel A. Beckett, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Susan M. Landau, John C. Morris, Kwangsik T. Nho, Rachel Nosheny, Ozioma Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew Saykin, Leslie M. ShawArthur W. Toga, Duygu Tosun

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.

Original language	English
Pages (from-to)	652-694
Number of pages	43
Journal	Alzheimer's and Dementia
Volume	20
Issue number	1
DOIs	https://doi.org/10.1002/alz.13449
State	Published - Jan 2024

Keywords

Alzheimer's Disease Neuroimaging Initiative
Alzheimer's disease clinical trials
Alzheimer's disease subtypes
amyloid
cerebrovascular disease
co-pathologies
diagnosis
disease progression
generalizability
neurodegeneration
neuroinflammation
plasma biomarkers
prediction
resilience
tau

Access to Document

10.1002/alz.13449

Cite this

Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., Morris, J. C., Nho, K. T., Nosheny, R., Okonkwo, O., Perrin, R. J., Petersen, R. C., Rivera Mindt, M., Saykin, A., ... Tosun, D. (2024). The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Alzheimer's and Dementia, 20(1), 652-694. https://doi.org/10.1002/alz.13449

@article{b2744eb5f7194bf08cbd557e63d0bcbd,

title = "The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022",

abstract = "The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.",

keywords = "Alzheimer's Disease Neuroimaging Initiative, Alzheimer's disease clinical trials, Alzheimer's disease subtypes, amyloid, cerebrovascular disease, co-pathologies, diagnosis, disease progression, generalizability, neurodegeneration, neuroinflammation, plasma biomarkers, prediction, resilience, tau",

author = "Veitch, {Dallas P.} and Weiner, {Michael W.} and Melanie Miller and Aisen, {Paul S.} and Ashford, {Miriam A.} and Beckett, {Laurel A.} and Green, {Robert C.} and Danielle Harvey and Jack, {Clifford R.} and William Jagust and Landau, {Susan M.} and Morris, {John C.} and Nho, {Kwangsik T.} and Rachel Nosheny and Ozioma Okonkwo and Perrin, {Richard J.} and Petersen, {Ronald C.} and {Rivera Mindt}, Monica and Andrew Saykin and Shaw, {Leslie M.} and Toga, {Arthur W.} and Duygu Tosun",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2024",

month = jan,

doi = "10.1002/alz.13449",

language = "English",

volume = "20",

pages = "652--694",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "1",

}

Veitch, DP, Weiner, MW, Miller, M, Aisen, PS, Ashford, MA, Beckett, LA, Green, RC, Harvey, D, Jack, CR, Jagust, W, Landau, SM, Morris, JC, Nho, KT, Nosheny, R, Okonkwo, O, Perrin, RJ, Petersen, RC, Rivera Mindt, M, Saykin, A, Shaw, LM, Toga, AW & Tosun, D 2024, 'The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022', Alzheimer's and Dementia, vol. 20, no. 1, pp. 652-694. https://doi.org/10.1002/alz.13449

TY - JOUR

T1 - The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment

T2 - A review of ADNI studies from 2021 to 2022

AU - Veitch, Dallas P.

AU - Weiner, Michael W.

AU - Miller, Melanie

AU - Aisen, Paul S.

AU - Ashford, Miriam A.

AU - Beckett, Laurel A.

AU - Green, Robert C.

AU - Harvey, Danielle

AU - Jack, Clifford R.

AU - Jagust, William

AU - Landau, Susan M.

AU - Morris, John C.

AU - Nho, Kwangsik T.

AU - Nosheny, Rachel

AU - Okonkwo, Ozioma

AU - Perrin, Richard J.

AU - Petersen, Ronald C.

AU - Rivera Mindt, Monica

AU - Saykin, Andrew

AU - Shaw, Leslie M.

AU - Toga, Arthur W.

AU - Tosun, Duygu

PY - 2024/1

Y1 - 2024/1

N2 - The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.

AB - The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co-pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI-4 aims to address by enrolling a diverse cohort.

KW - Alzheimer's Disease Neuroimaging Initiative

KW - Alzheimer's disease clinical trials

KW - Alzheimer's disease subtypes

KW - amyloid

KW - cerebrovascular disease

KW - co-pathologies

KW - diagnosis

KW - disease progression

KW - generalizability

KW - neurodegeneration

KW - neuroinflammation

KW - plasma biomarkers

KW - prediction

KW - resilience

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=85170667482&partnerID=8YFLogxK

U2 - 10.1002/alz.13449

DO - 10.1002/alz.13449

M3 - Review article

C2 - 37698424

AN - SCOPUS:85170667482

SN - 1552-5260

VL - 20

SP - 652

EP - 694

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 1

ER -

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this